Nuvectis Pharma, Inc. (NVCT)
24.49
+0.12
(+0.49%)
USD |
NASDAQ |
Sep 04, 16:00
24.47
-0.02
(-0.08%)
After-Hours: 20:00
Nuvectis Pharma Research and Development Expense (Quarterly) : 4.684M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.684M |
| March 31, 2026 | 4.106M |
| December 31, 2025 | 5.086M |
| September 30, 2025 | 5.774M |
| June 30, 2025 | 3.613M |
| March 31, 2025 | 3.68M |
| December 31, 2024 | 4.496M |
| September 30, 2024 | 2.819M |
| June 30, 2024 | 2.943M |
| March 31, 2024 | 2.66M |
| December 31, 2023 | 4.265M |
| Date | Value |
|---|---|
| September 30, 2023 | 4.486M |
| June 30, 2023 | 4.262M |
| March 31, 2023 | 2.367M |
| December 31, 2022 | 4.397M |
| September 30, 2022 | 4.52M |
| June 30, 2022 | 2.505M |
| March 31, 2022 | 1.805M |
| December 31, 2021 | 1.144M |
| September 30, 2021 | 4.156M |
| June 30, 2021 | 4.245M |
| March 31, 2021 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Decoy Therapeutics, Inc. | 1.304M |
| Unicycive Therapeutics, Inc. | 2.788M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |